GSK scratches itch for phase 3 win, hitting goal in liver disease trial to open up untapped market

A phase 3 trial of GSK’s linerixibat in a liver disease has hit its primary endpoint, keeping the drugmaker on track to launch the first treatment for the relentless itching experienced by some patients.